REMODEL data point to inflammation and vessel pathways in semaglutide kidney effects

New mechanistic findings from the REMODEL trial suggest that semaglutide's effects on the kidney may work through inflammation and blood-vessel biology rather than through blood sugar or weight loss alone — and may not be limited to diabetes, investigators said at the World Congress of Nephrology 2026 in Yokohama, Japan ^[1].

REMODEL was designed as a companion to the FLOW trial, which showed reductions in heart and kidney outcomes with semaglutide in people with type 2 diabetes and chronic kidney disease ^[1]. According to David Cherney, MD, PhD, who discussed the results in a Kidney Compass interview published March 30, 2026, FLOW answered whether the drug helps; REMODEL was built to ask why ^[1]. Earlier analyses had suggested the kidney protection could not be fully explained by improvements in blood sugar control, weight loss or blood pressure ^[1].

The trial enrolled patients with type 2 diabetes and chronic kidney disease. Its primary outcome was MRI-derived measures of kidney oxygenation. Secondary endpoints included albuminuria, kidney function, and markers of fibrosis, intrarenal fat and inflammation, and a subset of participants had paired kidney biopsies so researchers could look directly at cellular and molecular changes inside the kidney ^[1].

Semaglutide showed no effect on kidney oxygenation ^[1]. Cherney reported that it did reduce perirenal and hilar fat, the fat around and near the kidney, a result he and host Brendon Neuen, MBBS, PhD, called notable because of emerging hypotheses about local fat's role in kidney injury ^[1]. The trial also showed improvements in markers of fibrosis and inflammation, including changes in endothelial cell biology — the cells that line blood vessels — and reductions in inflammatory cell populations, which the investigators described as signs of a direct effect within the kidney ^[1].

Cherney reported that semaglutide reduced albuminuria by approximately 40% ^[1]. Albuminuria, excess protein in the urine, is a marker of kidney damage. Subgroup analyses showed consistent effects whether or not participants were already taking an SGLT2 inhibitor when the trial began ^[1]. Neuen said that fits with other evidence pointing to complementary mechanisms between the two drug classes ^[1].

Both investigators said the mechanisms seen in REMODEL, particularly inflammation and endothelial dysfunction, are likely not specific to diabetes and may extend to non-diabetic kidney disease ^[1]. Cherney argued for reframing semaglutide as a kidney-directed therapy, independent of its effects on glucose or weight ^[1]. They also discussed possible ways perirenal fat could harm the kidney — physical compression of kidney structures and metabolic activity of fat tissue driving cytokine-mediated injury — and both said these ideas need more investigation ^[1].

It has not been reported how many people took part in REMODEL, how long they were followed, or whether the marker changes translate into fewer cases of kidney failure, dialysis or transplant. The roughly 40% albuminuria reduction is a change in a laboratory marker, not a demonstrated reduction in those hard outcomes in this trial ^[1].

Disclosures: Neuen reports financial ties to AstraZeneca, Bayer, Boehringer Ingelheim and Janssen, among others; Cherney reports ties to Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Abbvie, Janssen, Amgen, Bayer, Gilead, CSL-Behring, Otsuka, Novartis and GSK, among others ^[1].

Why it matters for patients

For people who already have type 2 diabetes and chronic kidney disease, these findings add a proposed explanation to what FLOW showed about outcomes — that the benefit is not simply a side effect of lower blood sugar or weight ^[1]. That distinction matters because it suggests the drug could matter for kidneys in ways that are separate from why someone started taking it.

The findings concern semaglutide, the active ingredient in Ozempic, Wegovy and Rybelsus ^[1].

For people whose kidney disease is not caused by diabetes, the relevance is still a hypothesis. Cherney said the inflammation and endothelial pathways are likely not diabetes-specific, but REMODEL studied only patients with type 2 diabetes and chronic kidney disease, so whether semaglutide protects kidneys in non-diabetic disease has not been tested ^[1].

For people already taking an SGLT2 inhibitor, the subgroup data suggest the effects were consistent regardless of that use, which the investigators described as complementary rather than overlapping ^[1].

The endpoints measured here — kidney fat, fibrosis markers, inflammatory cells and albuminuria — are not the same as feeling better or avoiding dialysis. No change in approval or labeling for any semaglutide product has been reported on the basis of REMODEL ^[1].

What happens next

No timeline for a trial of semaglutide in non-diabetic kidney disease has been disclosed ^[1]. The investigators described both the non-diabetic question and the perirenal fat hypotheses as areas that warrant further investigation ^[1]. No regulatory submission or labeling change tied to these findings has been reported ^[1].